Alx Oncology Holdings (ALXO) Net Income towards Common Stockholders (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$21.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 29.68% year-over-year to -$21.6 million; the trailing twelve-month figure through Mar 2026 stood at -$96.0 million (up 27.86% YoY), and the FY2025 full-year result was -$497000.0, up 99.53% from the prior year.
• Net Income towards Common Stockholders rose to -$21.6 million in Q1 2026, from -$23.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$21.6 million in Q1 2026 to a low of -$51.0 million in Q3 2023.
• A 5-year average of -$32.9 million and a median of -$30.7 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders slumped 111.63% in 2022 and soared 39.77% in 2024, its largest moves.
• Tracing ALXO's Net Income towards Common Stockholders over 5 years: stood at -$30.6 million in 2022, then tumbled by 49.01% to -$45.7 million in 2023, then soared by 35.36% to -$29.5 million in 2024, then climbed by 21.83% to -$23.1 million in 2025, then increased by 6.3% to -$21.6 million in 2026.
• Business Quant data shows ALXO's Net Income towards Common Stockholders at -$21.6 million in Q1 2026, -$23.1 million in Q4 2025, and -$22.1 million in Q3 2025.